HC Wainwright resumed coverage on Paratek Pharmaceuticals
$PRTK
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright resumed coverage of Paratek Pharmaceuticals with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2023 | $7.00 → $5.00 | Buy | Jefferies |
| 4/17/2023 | $24.00 | Buy | BTIG Research |
| 2/10/2022 | $11.00 | Buy → Strong Buy | WBB Securities |
| 11/9/2021 | $28.00 → $27.00 | Buy | HC Wainwright & Co. |
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy
Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209817, Application Classification: Labeling